Patient-centered developments in colon- and rectal cancer with a multidisciplinary international team: From translational research to national guidelines

Table 1 Individualized response prediction in patients with hepatic artery infusion[42]

Response predictor	Clinical outcome		Median survival (mo, range)
	Beneficial response (%)	No response (%)
HTCA
Sensitive	58	42	28 (3-75)
Resistant	33	67	19 (5-48)
TS
Sensitive	64	36	26 (6-48)
Resistant	20	80	26 (3-75)
HTCA + TS
Sensitive	77	23	32 (5-75)
Resistant	9	91	17 (3-28)

HTCA: Human tumor colony assay; TS: Thymidylate synthase.

Table 2 Influence of quantitative thymidylate synthase expression in individual metastatic biopsies on response rates and median survival times in patients with metastatic colon- or rectal cancer[27]

	TS low		TS high
	5-FU + FA	5-FU + FA + Irinotecan	5-FU + FA	5-FU + FA + Irinotecan
Patients (n = 119)	39	38	23	19
Median survival (95%CI)	18.4 (12.1-25.2)	18.8 (12.0-23.2)	19.2 (5.6-33.3)	15.2 (8.4-26.0)
Beneficial response1 (%)	33	45	22	47, P = 0.0773
No response2 (%)	67	55	78	53

¹Complete and partial response.

²Stable and progressive disease.

³Fisher‘s exact test (one-sided).

TS: Thymidylate synthase; 5-FU: 5-Fluorouracil; FA: Folinic acid; CI: Confidence interval.